Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study - Summary - MDSpire

Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study

  • By

  • Anas Z. Nourelden

  • Parker R. Scott

  • Sam I. Hooshmand

  • Izabela Mazur

  • Felicia Mada

  • Tesiley Ash

  • Nidhi Patel

  • Jacob Rube

  • Kalyan Yarraguntla

  • Carey Deluca

  • Patti Yager-Stone

  • Ryan Havens

  • Mitchell Wallin

  • Anza B. Memon

  • July 16, 2026

Share

Objective:

To characterize real-world infusion-related reactions (IRRs) associated with ublituximab and describe premedication practices across participating centers.

Approach:
  • Study Design: A multicenter retrospective study involving ublituximab-treated MS patients from five MS centers in the U.S., utilizing existing medical records.
  • Data Collection: Demographics, MS phenotype, premedication regimens, and IRRs were collected and analyzed using statistical methods.
Key Findings:
  • 34.8% of patients experienced IRRs.
  • All patients received premedication, with acetaminophen dose significantly associated with IRR occurrence (p = 0.006).
  • All observed IRRs were mild to moderate in severity.
Interpretation:

No independent predictors of IRRs were identified, and the timing and symptom patterns of IRRs varied.

Limitations:
  • Retrospective design may limit the ability to establish causation.
  • Data collected from a convenience sample may not represent the broader population.
Conclusion:

Ublituximab infusions were generally well tolerated, with a significant portion of patients experiencing mild to moderate IRRs.

Original Source(s)

Infusion-related reactions and premedication patterns in ublituximab-treated multiple sclerosis patients: a multicenter real-world study

  • by Anas Z. Nourelden, Parker R. Scott, Sam I. Hooshmand, Izabela Mazur, Felicia Mada, Tesiley Ash, Nidhi Patel, Jacob Rube, Kalyan Yarraguntla, Carey Deluca, Patti Yager-Stone, Ryan Havens, Mitchell Wallin, Anza B. Memon

  • July 16, 2026

Related Content

Stem cell-derived extracellular vesicles as immunomodulatory agents: targeting pathological crosstalk in systemic lupus erythematosus and multiple sclerosis

Multiple sclerosis as a biological and clinical continuum: from risk factors to the early stages of disease

Head-to-Head Trial in Relapsing MS

The phase 3 OVERLORD-MS trial compared 2 anti-CD20 therapies in previously untreated adults with newly diagnosed relapsing multiple sclerosis and recent inflammatory disease activity.